Key facts
- TearExo’s last known valuation is $4.6M (May 2025).
- It has raised $700K; the latest was Early Stage VC ($350K) in May 2025.
- Notable investors include Intellectual Property Acceleration Program for Startups, Mirai Cross, Leave a Nest Capital, Chugin Capital Partner, Japan Startup Support Association — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for TearExo
- ·The full record, as it builds
Funding rounds
No funding rounds for TearExo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TearExo
Developer of a research platform intended to detect cancer using human tears. The company's platform specializes in using tear fluid, which can be easily self-collected instead of blood, enabling researchers to reduce the time of specimen collection, lower the time and effort of making an appointment, and lower the examination hurdles.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2022
- Website
- tearexo.jp/
- Ownership
- Privately Held (backing)
TearExo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TearExo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TearExo in its N-PORT filings yet. We sweep new filings monthly.